The global amylin analogs market was valued at USD 652.8 million in 2025 and is projected to reach USD 1,136.3 million by the end of 2035, representing a compound annual growth rate (CAGR) of 5.7% during the forecast period. This trajectory reflects steady, clinically driven adoption of amylin-based therapies as adjuncts to insulin and GLP-1 treatments, growing investment in next-gene... https://www.researchnester.com/reports/amylin-analogs-market/7710